دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Mitogen-Activated Protein Kinase Inhibitor Selumetinib Fails to Increase the Complete Response Rate of Radioactive Iodine Alone in High-Risk Differentiated Thyroid Cancer: Lessons From the Phase III ASTRA Study.
Brose, Marcia S. MD, PhD 1,,; Pryma, Daniel A. MD 2,; Newbold, Kate L. MD 3,
doi : 10.1200/JCO.22.00556
Volume 40(17) pgs. 1847-1964 June 10, 2022
Risk of Peritoneal Cancer After Risk-Reducing Bilateral Salpingo-Oophorectomy for Women With Germline BRCA Pathogenic Variants: A Cause for Concern or Potentially Avoidable?.
Phillips, Kelly-Anne MBBS, MD 1,2,; Friedlander, Michael L. MBChB, PhD 3,4,
doi : 10.1200/JCO.22.00325
Revisiting the Threshold for Cancer Genetics Referral in Patients With Wilms Tumor.
Turner, Joyce T. MS 1,2,; Hill, D. Ashley MD 3,; Dome, Jeffrey S. MD, PhD 2,,
doi : 10.1200/JCO.22.00411
Tumor Heterogeneity Research and Innovation in Biologically Based Radiation Therapy From the National Cancer Institute Radiation Research Program Portfolio.
Buchsbaum, Jeffrey C. PhD, MD, AM 1,; Espey, Michael G. PhD 1; Obcemea, Ceferino PhD 1; Capala, Jacek PhD 1; Ahmed, Mansoor PhD 1; Prasanna, Pataje G. PhD 1; Vikram, Bhadrasain PhD 1; Hong, Julie A. MS 1; Teicher, Beverly PhD 1; Aryankalayil, Molykutty J. PhD 1; Bylicky, Michelle A. PhD 1; Coleman, C. Norman MD 1,
doi : 10.1200/JCO.21.02579
Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA).
Ho, Alan L. MD, PhD 1,,; Dedecjus, Marek PhD 2,; Wirth, Lori J. MD 3,; Tuttle, R. Michael MD 4,; Inabnet, William B. III MD 5,6; Tennvall, Jan PhD 7; Vaisman, Fernanda PhD 8,; Bastholt, Lars MD 9,; Gianoukakis, Andrew G. MD 10,11,; Rodien, Patrice PhD 12,; Paschke, Ralf PhD 13,; Elisei, Rossella MD 14; Viola, David MD 14; So, Karen MD 15,; Carroll, Danielle MD 15,; Hovey, Tina MSc 16,; Thakre, Bhavana MD 17; Fagin, James A. MD 4,; the ASTRA investigator group
doi : 10.1200/JCO.21.00714
Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis.
Steenbeek, Miranda P. MD 1,; van Bommel, Majke H.D. MD 1; Bulten, Johan MD, PhD 2; Hulsmann, Julia A. MD 1; Bogaerts, Joep MD 2; Garcia, Christine MD, PhD 3; Cun, Han T. MD, PhD 4; Lu, Karen H. MD, PhD 4; van Beekhuizen, Heleen J. MD, PhD 5; Minig, Lucas MD, PhD 6; Gaarenstroom, Katja N. MD, PhD 7; Nobbenhuis, Marielle MD, PhD 8,; Krajc, Mateja MD, PhD 9,; Rudaitis, Vilius MD, PhD 10,; Norquist, Barbara M. MD, PhD 11; Swisher, Elizabeth M. MD, PhD 11,; Mourits, Marian J.E. MD, PhD 12; Massuger, Leon F.A.G. MD, PhD 1; Hoogerbrugge, Nicoline MD, PhD 13; Hermens, Rosella P.M.G. PhD 14; IntHout, Joanna PhD 15; de Hullu, Joanne A. MD, PhD 1
doi : 10.1200/JCO.21.02016
Prevalence of (Epi)genetic Predisposing Factors in a 5-Year Unselected National Wilms Tumor Cohort: A Comprehensive Clinical and Genomic Characterization.
Hol, Janna A. MD 1; Kuiper, Roland P. PhD 1,2; van Dijk, Freerk MSc 1; Waanders, Esme PhD 2; van Peer, Sophie E. MD 1; Koudijs, Marco J. PhD 1,2; Bladergroen, Reno BSc 1; van Reijmersdal, Simon V. BSc 1; Morgado, Lionel M. PhD 1; Bliek, Jet PhD 3; Lombardi, Maria Paola PhD 3; Hopman, Saskia PhD 2; Drost, Jarno PhD 1,4,; de Krijger, Ronald R. PhD 1,5; van den Heuvel-Eibrink, Marry M. PhD 1; Jongmans, Marjolijn C.J. PhD 1,2,
doi : 10.1200/JCO.21.02510
Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery.
Pfob, Andre 1,2; Sidey-Gibbons, Chris PhD 2,3; Rauch, Geraldine PhD 4,; Thomas, Bettina MD 5,; Schaefgen, Benedikt MD 1; Kuemmel, Sherko MD 6,; Reimer, Toralf MD 7,; Hahn, Markus MD 8; Thill, Marc MD 9,; Blohmer, Jens-Uwe MD 10,; Hackmann, John MD 11; Malter, Wolfram MD 12,; Bekes, Inga MD 13; Friedrichs, Kay MD 14; Wojcinski, Sebastian MD 15; Joos, Sylvie MD 16; Paepke, Stefan MD 17,; Degenhardt, Tom MD 18,; Rom, Joachim MD 19,; Rody, Achim MD 20,; van Mackelenbergh, Marion MD 20,; Banys-Paluchowski, Maggie MD 20,21,; Gro[latin sharp s]e, Regina MD 22; Reinisch, Mattea MD 6,; Karsten, Maria MD 10,; Golatta, Michael MD 1,; Heil, Joerg MD 1,,
doi : 10.1200/JCO.21.02439
Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer.
Park, Sehhoon MD, PhD 1,; Ock, Chan-Young MD, PhD 2,; Kim, Hyojin MD, PhD 3; Pereira, Sergio PhD 2,; Park, Seonwook PhD 2,; Ma, Minuk MS 2,; Choi, Sangjoon MD 4; Kim, Seokhwi MD, PhD 5; Shin, Seunghwan MD 2,; Aum, Brian Jaehong PhD 2,; Paeng, Kyunghyun MS 2,; Yoo, Donggeun PhD 2,; Cha, Hongui PhD 1; Park, Sunyoung PhD 1; Suh, Koung Jin MD 6; Jung, Hyun Ae MD, PhD 1; Kim, Se Hyun MD, PhD 6,; Kim, Yu Jung MD, PhD 6; Sun, Jong-Mu MD, PhD 1; Chung, Jin-Haeng MD, PhD 3; Ahn, Jin Seok MD, PhD 1,; Ahn, Myung-Ju MD, PhD 1,; Lee, Jong Seok MD, PhD 6; Park, Keunchil MD, PhD 1,; Song, Sang Yong MD, PhD 4,; Bang, Yung-Jue MD, PhD 7,; Choi, Yoon-La MD, PhD 4,; Mok, Tony S. MD 8,; Lee, Se-Hoon MD, PhD 1,9,,
doi : 10.1200/JCO.21.02010
Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial.
Rini, Brian I. MD 1,,; Moslehi, Javid J. MD 2,3,; Bonaca, Marc MD, MPH 4,; Schmidinger, Manuela MD 5,; Albiges, Laurence MD, PhD 6,; Choueiri, Toni K. MD 7,; Motzer, Robert J. MD 8,; Atkins, Michael B. MD 9,; Haanen, John MD, PhD 10,; Mariani, Mariangela PhD 11,; Wang, Jing PhD 12,; Hariharan, Subramanian MD 13,; Larkin, James MD, PhD 14,
doi : 10.1200/JCO.21.01806
Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma.
Carvajal, Richard D. MD 1,; Nathan, Paul MBBS, PhD 2,; Sacco, Joseph J. MBChB, MSc, PhD 3,4,; Orloff, Marlana MD 5,; Hernandez-Aya, Leonel F. MD 6,; Yang, Jessica MD 1; Luke, Jason J. MD 7,8,; Butler, Marcus O. MD 9,; Stanhope, Sarah PhD 10,; Collins, Laura MSc 10,; McAlpine, Cheryl PhD 10,; Holland, Chris MSc 11,; Abdullah, Shaad E. MD 11,; Sato, Takami MD, PhD 5,,
doi : 10.1200/JCO.21.01805
Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute.
Chihara, Dai MD, PhD 1,2,,; Huang, Erich P. PhD 3; Finnigan, Shanda R. MPH, RN 4; Cordes, Lisa M. PharmD 5; Skorupan, Nebojsa MD 2; Fukuda, Yoko MD 4; Rubinstein, Larry V. PhD 3,; Ivy, S. Percy MD 4; Doroshow, James H. MD 4; Nastoupil, Loretta J. MD 1,; Flowers, Christopher R. MD, MSc 1,; Takebe, Naoko MD, PhD 4
doi : 10.1200/JCO.21.02190
Can Systemic Control Be Achieved in the Treatment of Oligometastatic Hepatocellular Cancer With Hepatic Artery Infusion Fluorouracil, Leucovorin, and Oxaliplatin Treatment?.
Sutcuoglu, Osman MD; Ulas Kahya, Burcu MD; Ozdemir, Nuriye MD; Yaz[latin dotless i]c[latin dotless i], Ozan MD
doi : 10.1200/JCO.22.00047
Clinical Utility of Precision Medicine in Early Breast Cancer: What Is the Optimal Framework to Develop Precision Medicine?.
Nozawa, Kazuki MD; Hattori, Masaya MD; Yoshimura, Akiyo MD, PhD; Iwata, Hiroji MD, PhD
doi : 10.1200/JCO.22.00153
Reply to K. Nozawa et al.
Schneider, Bryan P. MD; Ballinger, Tarah J. MD; Jiang, Guanglong MS; Shen, Fei MD; Kassem, Nawal MD; Miller, Kathy D. MD
doi : 10.1200/JCO.22.00288
